Sotorasib demonstrated significant benefit in patients with KRAS G12C–mutated advanced non–small cell lung cancer who progressed after standard treatment, according to results from the phase 2 portion of the CodeBreaK 100 trial .
Focusing on VEGF TKIs available for the treatment of patients with metastatic renal cell carcinoma, the panel discusses the goals of therapy in the third-line…
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for…
In a retrospective study in patients with hepatocellular carcinoma, 40% of patients developed irAEs after receiving the first and second doses of immunotherapy.
Lori J. Wirth, MD, discusses some of the ongoing clinical trials investigating innovative therapies or combinations for the treatment of patients with thyroid cancer.
Tisotumab vedotin is now an FDA-approved treatment for patients with recurrent or metastatic cervical cancer.
Dr. Bose discusses when he typically initiates ruxolitinib for his intermediate- or high-risk myelofibrosis patients.
Updated guidelines for small cell lung cancer were developed with an expert panel assembled by the American Society of Clinical Oncology and Ontario Health.
New data from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan could become a new standard of care for patients with HER2-low and HER2-ultralow metastatic breast…
Trastuzumab-strf, a biosimilar of trastuzumab, has received FDA approval for treating HER2-overexpressing breast cancer and metastatic gastric cancer.
Dr. Bose reviews the efficacy and safety findings from various studies on JAK inhibitors, including JAKARTA, PERSIST-1, PERSIST-2, SIMPLIFY-1 & 2, and MOMENTUM, and how…
